About Ebixa
Overcoming everyday challenges in Alzheimer’s disease
Ebixa is more effective than placebo at controlling the symptoms of Alzheimer's disease, and is as well tolerated as placebo. Ebixa is indicated for the treatment of moderate to severe Alzheimer’s disease.
Ebixa is a specific, uncompetitive NMDA-receptor antagonist, with a novel mechanism of action that targets the glutamatergic signalling in the brain.
Please use the left-hand menu to access more detailed information about how Ebixa may benefit in moderate to severe Alzheimer's disease.
Published: 02/06/2006 Last updated: 18/05/2010